Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Resolution of warts
研究概览
简要总结
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.
详细描述
39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 9 Years 至 45 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic multiple cutaneous
排除标准
- •Hypersensitivity to Candida antigen
- •Immunosuppressive disorders
- •Previous wart therapy in the last month
研究组 & 干预措施
Wart Patients
Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
干预措施: Candida antigen (Biological)
结局指标
主要结局
Resolution of warts
时间窗: 12 weeks
100% clearance of warts
次要结局
- Recurrence(6 months)
研究者
Noha M Hammad, MD
Principal investigator
Zagazig University